Loop Isolation-based Uploading Pre-conditioning
1 other identifier
observational
60
1 country
1
Brief Summary
Myocardial protection is of crucial importance for surgical coronary revascularization in patients with ischaemic heart diseases. The investigators proposed loop isolation-based uploading preconditioning to protect heart from ischemic-reperfusion damage (LiuPhD) as a novel cardioprotective strategy, and applied to patients who underwent on-pump coronary artery bypass grafting (CABG).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2016
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2018
CompletedFirst Submitted
Initial submission to the registry
December 3, 2018
CompletedFirst Posted
Study publicly available on registry
December 6, 2018
CompletedDecember 7, 2018
December 1, 2018
2.9 years
December 3, 2018
December 5, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Concentration of postoperative maximum cardiac troponin T
postoperative maximum concentration serum cardiac troponin T (cTnT) as markers of myocardial injury.
up to 30 days
Interventions
declamping was not done until heart could resume normal mechanical activities and sustain well for three minutes in terms of heart rate, rhythm, and myocardial contractility via continuous antegrade warm blood delivery closely following TWBC reperfusion.
Eligibility Criteria
The LiuPhD (Loop Isolation-based Uploading Preconditioning to Protect Heart from ischemic-reperfusion Damage) study was a prospective, open-label, single-arm, first-in-man trial on the use of LiuPhD strategy for myocardial protection in patients who underwent surgical coronary revascularization.
You may qualify if:
- Patients scheduled for a first, elective, isolated, open thoracotomy, on-pump CABG were eligible for enrollment if they if they had coronary angiography-confirmed unprotected left main disease, 3-vessel disease with or without proximal LAD artery disease, or 2-vessel disease with proximal LAD artery disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
TEDA International Cardiovascular Hospital
Tianjin, Tianjin Municipality, 300457, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Investigator
Study Record Dates
First Submitted
December 3, 2018
First Posted
December 6, 2018
Study Start
January 1, 2016
Primary Completion
December 1, 2018
Study Completion
December 1, 2018
Last Updated
December 7, 2018
Record last verified: 2018-12